Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
WDPCP CRISPR/Cas9 KO Plasmid (h): sc-405848
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- WDPCP CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the WDPCP genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: WDPCP Antibody (A-5): sc-514151
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
WDPCP CRISPR/Cas9 KO Plasmid (h) | sc-405848 | 20 µg | $397.00 |
Overview
WDPCP (WD repeat-containing planar cell polarity effector) encodes a centrosome- and cilium-associated protein required for primary ciliogenesis and planar cell polarity–related organization. WDPCP supports basal body docking and axoneme formation and contributes to the assembly or function of ciliary transition zone modules that coordinate trafficking of signaling components. Through its role in cilia, WDPCP influences cilia-dependent pathways such as Hedgehog signaling and broader cytoskeletal and polarity programs important for epithelial tissue architecture. Disruption of WDPCP function is linked to ciliopathy phenotypes, including developmental abnormalities and multisystem defects consistent with impaired ciliary signaling and morphogenesis.
WDPCP CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the WDPCP gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the WDPCP together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the WDPCP open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish WDPCP protein expression.
This CRISPR knockout system enables efficient generation of WDPCP-deficient cell models for investigation of WDPCP signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting WDPCP exon(s) critical for WDPCP function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple WDPCP genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by WDPCP CRISPR/Cas9 KO Plasmid (h) and WDPCP CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the WDPCP locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by WDPCP HDR Plasmid (h) and WDPCP HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by WDPCP homology arms to support homology-directed repair at defined WDPCP target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.